Patents Assigned to Sankyo Company Limited
  • METHOD FOR PREDICTING RESPONSIVENESS TO PHOSPHATIDYLSERINE SYNTHASE 1 INHIBITOR
    Publication number: 20180073084
    Abstract: It is intended to develop a therapeutic strategy for specifically targeting cancer cells having the functional suppression of PSS2. The present inventors have found that PSS1 and PSS2 are in a synthetic lethal relationship, and treatment inhibiting PSS1 serves as a promising approach for the treatment of cancer having the functional suppression of PSS2. It has also been revealed that this therapeutic strategy permits efficient treatment based on companion diagnostics because a PSS1 inhibitor can be administered to a subject selected by using the functional suppression of PSS2 as an index.
    Type: Application
    Filed: March 15, 2016
    Publication date: March 15, 2018
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yohei YOSHIHAMA, Tatsuya INOUE
  • 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS
    Publication number: 20180072732
    Abstract: The present invention relates to a pyrazole derivative of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, stereoisomer thereof or a deuterium form thereof, wherein, n, Y, Ra, R1, R2, R3, R4, R5 and R6 are as defined hereinafter in the specification, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) as inhibitors of phosphatidylinositol-3-kinase (PI3K), which can be used for treating or preventing inflammatory, autoimmune, orphan and hyperproliferative disease and disorder.
    Type: Application
    Filed: March 29, 2016
    Publication date: March 15, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kirandeep Kaur Samby, Yogesh Baban Surase, Sagar Ramdas Amale, Suresh Kumar Gorla, Priyanka Patel, Ashwani Kumar Verma
  • ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE
    Publication number: 20180071403
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.
    Type: Application
    Filed: November 22, 2017
    Publication date: March 15, 2018
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Takeshi MASUDA, Hideki MIYAZAKI, Yuji KASUYA, Yuki ABE, Yusuke OGITANI
  • ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
    Publication number: 20180037656
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 8, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yoshihara HIRUMA, Eisuki TSUDA
  • PHARMACEUTICAL FOR PROPHYLAXIS OR TREATMENT OF HYPERTENSION
    Publication number: 20180036281
    Abstract: A pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension. The pharmaceutical is characterized by comprising (i) a specific mineralocorticoid receptor antagonist and (ii) one or more components selected from the following components (A) to (C), for administration simultaneously or separately at a time interval: (A) an angiotensin II receptor antagonist, (B) a calcium antagonist, and (C) a diuretic.
    Type: Application
    Filed: October 2, 2017
    Publication date: February 8, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kiyoshi Arai, Tsuyoshi Homma, Makoto Mizuno
  • Crystals of dispiropyrrolidine derivatives
    Patent number: 9884871
    Abstract: Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of Mdm2 are provided. The present invention provides crystals of (3?R,4?S,5?R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6?-chloro-4?-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2?-oxo-1?,2?-dihydrodispiro[cyclohexane-1,2?-pyrrolidine-3?,3?-indole]-5?-carboxamide or a salt thereof which inhibits Mdm2 and has anti-tumor activity. The present invention also provides a medicament comprising the same.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: February 6, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Shoko Yoshida, Yuuichi Sugimoto
  • Double-stranded polynucleotide
    Patent number: 9885036
    Abstract: It is intended to provide a double-stranded polynucleotide that is resistant to RNase and has RNA interference effect, etc. The present invention provides a double-stranded polynucleotide comprising sense and antisense strands comprising polynucleotides comprising a nucleotide unit of DNAs and 2?-O-methyl RNAs alternately combined.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 6, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Makoto Koizumi, Yasuhide Hirota
  • Pyridine compounds
    Patent number: 9879032
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: January 30, 2018
    Assignees: Daiichi Sankyo Company, Limited, Sandford Burnham Prebys Medical Discovery Institute
    Inventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuke Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki
  • Antibody-drug conjugate produced by binding through linker having hydrophilic structure
    Patent number: 9872924
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: January 23, 2018
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
  • TERPENOID DERIVATIVES
    Publication number: 20180016298
    Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 18, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
  • Promoter derived from human gene
    Patent number: 9862969
    Abstract: The present invention relates to a transfected mammalian host cell whose ability to secrete a foreign protein has been enhanced by using a foreign gene expression vector having a promoter derived from a human gene, and a method for producing the foreign protein using the host cell. A method for enhancing the production of a foreign protein to be used in a pharmaceutical protein product in a host cell such as a cultured mammalian cell is provided. A promoter derived from a human gene having a promoter activity higher than that of a cytomegalovirus (CMV) promoter in a host cell such as a cultured mammalian cell is provided.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: January 9, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventor: Kenji Murakami
  • Anti-DR5 antibodies, polynucleotides and methods
    Patent number: 9856321
    Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: January 2, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Takeshi Takizawa, Akiko Oguni, Tatsuji Matsuoka, Hiroko Yoshida, Yumi Matsui
  • PHARMACEUTICAL COMPOSITION FOR PROMOTION OF FIBRINOLYSIS
    Publication number: 20170368037
    Abstract: It is intended to provide a novel pharmaceutical composition that can promote fibrinolysis. The present invention provides a pharmaceutical composition for the promotion of fibrinolysis, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt. The present invention further provides a pharmaceutical composition for the promotion of fibrinolysis, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt and further comprising a TAFIa inhibitor.
    Type: Application
    Filed: December 25, 2015
    Publication date: December 28, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Taketoshi Furugori, Yoshiyuki Morishima
  • METHOD FOR PRODUCING PYRROLE DERIVATIVE, AND INTERMEDIATE THEREOF
    Publication number: 20170369438
    Abstract: The present invention provides a method for producing an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, and an intermediate thereof. A method for producing an atropisomer of a pyrrole derivative using a compound represented by (B) [wherein R1 represents a C1-C4 alkyl group, and R2 represents a 2-hydroxyethyl group or a carboxymethyl group] as a production intermediate.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Masashi Watanabe, Hiroshi Nagasawa, Noritada Sato
  • Anti-TROP2 antibody-drug conjugate
    Patent number: 9850312
    Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 26, 2017
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, SAPPORO MEDICAL UNIVERSITY
    Inventors: Toshinori Agatsuma, Shu Takahashi, Jun Hasegawa, Daisuke Okajima, Hirofumi Hamada, Miki Yamaguchi
  • Cycloalkane derivatives
    Patent number: 9845313
    Abstract: Disclosed herein are therapeutic agents and/or preventive agents for pain or therapeutic agents and/or preventive agents for a sodium channel associated disease.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: December 19, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tsuyoshi Shinozuka, Hiroyuki Kobayashi, Sayaka Suzuki, Kyosuke Tanaka, Hiroko Kimoto, Yuki Domon
  • OPHTHALMIC AQUEOUS COMPOSITION
    Publication number: 20170340644
    Abstract: An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 30, 2017
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoko ENDO, Kyohei TAKAHASHI, Shinya UMEZAKI
  • Orally disintegrating tablet and production process therefor
    Patent number: 9827200
    Abstract: Provided are an orally disintegrating tablet that quickly disintegrates when it is placed in the mouth or put into water, provides favorable taste, has a sufficient hardness in general production, transportation and use and is excellent in terms of storage stability, and a process for the production of the same which is excellent in terms of industrial production. An orally disintegrating tablet containing a drug, a crystalline cellulose having a bulk density of 0.23 g/cm3 or less (preferably from 0.10 g/cm3 to 0.23 g/cm3), a sugar alcohol and a pregelatinized starch.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: November 28, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Gaku Sekiguchi, Ryoichi Hayakawa, Yoshihiro Hara
  • Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
    Patent number: 9827199
    Abstract: An object is to provide a hydromorphone hydrochloride- or oxycodone hydrochloride hydrate-containing sustained-release pharmaceutical composition for oral administration that reliably exhibits its main pharmacological effect and has excellent formulation stability that avoids dose dumping of the principal drug, such as alcohol resistance. The present invention provides a sustained-release pharmaceutical composition comprising (A) hydromorphone hydrochloride or oxycodone hydrochloride hydrate, (B) hydroxypropyl methylcellulose acetate succinate having a median size (D50) of 40 ?m or smaller, (C) hydroxypropyl cellulose, and (D) a saccharide, wherein the content ratio of the component (C) to the component (B) by weight in the composition, (C)/(B), is 11/3 to 3/11.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: November 28, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Shuichi Yada, Hideki Yano, Kazuhiro Yoshida, Sachiko Fukui
  • Antibody targeting osteoclast-related protein siglec-15
    Patent number: 9815899
    Abstract: To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: November 14, 2017
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yoshiharu Hiruma, Eisuke Tsuda